TriSalus Life Sciences
TLSI
32 hedge funds and large institutions have $10M invested in TriSalus Life Sciences in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
14% more funds holding
Funds holding: 28 → 32 (+4)
9% more capital invested
Capital invested by funds: $9.21M → $10M (+$807K)
0.84% more ownership
Funds ownership: 6.57% → 7.41% (+0.84%)
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAP
Wealthcare Advisory Partners
West Chester,
Pennsylvania
|
+$3.41M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$331K |
| 3 |
MP
MSD Partners
New York
|
+$212K |
| 4 |
VI
Vestcor Inc
Fredericton,
New Brunswick, Canada
|
+$124K |
| 5 |
AGC
Angelo Gordon & Co
New York
|
+$110K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$1.18M |
| 2 |
EAM
Exos Asset Management
New York
|
-$683K |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$205K |
| 4 |
AC
Anson Capital
Tyrone,
Georgia
|
-$135K |
| 5 |
Millennium Management
New York
|
-$132K |
TLSI Hedge Fund Activity: Q3 2024 in Review
32 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q3 2024, worth a combined $10M — up 8.8% from $9.21M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TLSI positions and 6 closed out — a net gain of 4 holders — while 3 added to existing stakes and 9 trimmed.
The largest buyer was Wealthcare Advisory Partners, opening a new position worth an estimated $3.41M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $1.18M sold.
- 32 institutional investors held TriSalus Life Sciences (TLSI) as of Q3 2024, up from 28 in Q2 2024.
- Funds reported $10M of TriSalus Life Sciences stock for Q3 2024, up 8.8% quarter-over-quarter.
- 10 funds opened new TriSalus Life Sciences positions in Q3 2024 and 6 closed out, a net change of +4 holders.
- The largest TriSalus Life Sciences buyer in Q3 2024 was Wealthcare Advisory Partners, an estimated $3.41M added.
- The largest TriSalus Life Sciences seller in Q3 2024 was Highbridge Capital Management, an estimated $1.18M sold.
Based on aggregated 13F filings for Q3 2024.